In 2000, I received my Pharm.D. degree from the University of Lisbon, Portugal. During the same year, I enrolled in a doctoral program at the Karolinska Institute. My masters and doctoral studies focused on how oxygen levels mediate protein degradation of the hypoxia-inducible factors. These studies culminated in a Licentiate in 2005, and subsequently a Ph.D. in 2009, both in Cell and Molecular Biology.
Following my Ph.D., I continued at the Karolinska Institute as a postdoctoral fellow at the department of Clinical Neurosciences. During my postdoc, I investigated the cellular and molecular mechanisms involved in neovascular age-related macular degeneration, a particularly incident sight-threatening disease. My research elucidated a central role for hypoxia-inducible factor-1alpha in this disease.
Since 2012, I have been assigned as Head of Molecular and Cellular Research at St Erik Eye Hospital, affiliated to the Karolinska Institute. My present research is centered on cell-based and gene therapy strategies to target the hypoxia-inducible factors as potential therapeutic agents in ocular vascular diseases.
HIF-1 alpha and HIF-2 alpha induce angiogenesis and improve muscle energy recovery
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 2014;44(10):989-99
Identification of an Alternative Mechanism of Degradation of the Hypoxia-inducible Factor-1 alpha
JOURNAL OF BIOLOGICAL CHEMISTRY 2008;283(43):29375-84
Stabilized HIF-1 alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer
FASEB JOURNAL 2005;19(8):1365-7